Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

(2018) Robert P. Hirten et al.   Clinical Gastroenterology and Hepatology

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

(2018) Lydia C T Buer et al.   INFLAMMATORY BOWEL DISEASES

Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohnʼs Disease

(2017) Kayci Huff-Hardy et al.   INFLAMMATORY BOWEL DISEASES

Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy

(2017) Xavier Roblin et al.   Journal of Crohns & Colitis

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study

(2016) Yu Shi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease

(2016) Clara Yzet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biologics in inflammatory bowel disease: what are the data?

(2015) Justin Côté-Daigneault et al.   United European Gastroenterology Journal

Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study

(2012) Marte Lie Høivik et al.   GUT

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: remission rates achievable by current therapies for inflammatory bowel disease

(2011) L. Peyrin-Biroulet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS